Background: The Automated Fluorescent Immunoassay System (AFIAS) rotavirus assay (Boditech Med Inc., Chuncheon, Korea) is a new rapid antigen test for rotavirus detection. We evaluated the performance of this assay for detecting rotaviruses and their specific genotypes in clinical stool samples.
INTRODUCTION
Rotaviruses are the major cause of severe diarrheal disease in children below five years worldwide [1, 2] . An estimated 215,000 children died from severe rotavirus-related gastroenteritis in 2013, with most of these deaths occurring in developing countries [3] .
Rotaviruses has a genome of 11 double-stranded RNA segments surrounded by a triple-layered capsid consisting of a core, inner capsid, and an outer capsid layer [1, 2] . Based on the antigenic variants of the VP6 inner capsid protein, rotaviruses can be classified into nine serogroups (A-I). Group A rotaviruses are the principal agents of human infections. The outer capsid protein consists of two structural proteins, VP7 and VP4, which are used to classify rotaviruses into the VP7 (G) and VP4 (P) genotypes. Over 27 G and 37 P genotypes have been reported to date, and the genotypic distribution of rotavirus strains shows temporal and geographic fluctuations [1, 2] .
Accurate and rapid diagnosis of rotavirus infection is important to determine appropriate treatment and to prevent the unnecessary use of antibiotics and spread of the infection. Practi-cally, rotavirus infection can be diagnosed from stool samples by immunoassays and molecular diagnostic techniques, such as PCR. Immunoassays (immunochromatography, enzyme immunoassay, etc.) are the most widely used diagnostic methods in routine laboratories because of the rapid turn-around time and cost-effectiveness. The antibodies used in these assays are the most important factors determining detection efficiency for stool samples [4, 5] . Monoclonal antibodies targeting the VP6 inner capsid protein, which is known to have epitopes in common with most rotavirus genotypes, are widely used in rotavirus detection immunoassays [6] . As over 27 G and 37 P genotypes of rotavirus have been reported, it is necessary to confirm that a given rotavirus detection immunoassay will be able to detect most of the numerous rotavirus genotypes. However, there is little information available on genotype detectability of commercial rotavirus immunoassays because genotype analysis of rotavirus has been performed at only a few rotavirus research laboratories, not at general clinical laboratories. Therefore, genotype detectability of rotavirus immunoassays should be evaluated.
The Automated Fluorescent Immunoassay System (AFIAS) rotavirus assay (Boditech Med Inc., Chuncheon, Korea) is a newly developed automated fluorescent lateral-flow immunoassay for the rapid detection of rotaviruses in human stool samples [7] . We evaluated its performance for detecting rotaviruses in stool samples from Korean patients and compared the results with those of other conventional assays. In addition, we examined which genotypes can be detected with the AFIAS rotavirus assay.
METHODS

Stool samples
This study was approved by the Institutional Review Board of Hallym University, Dongtan Sacred Heart Hospital (IRB No. 2016-105). A total of 103 rotavirus-positive and 103 rotavirus-negative stored stool samples were used. The stool samples were collected from 206 gastroenteritis patients admitted to Hallym University Dontan Secred Heart Hospitals between October 2015 and March 2016. Age ranged from 0 to 90 years (median, three years); 87.4% of the positive samples were obtained from patients younger than five years. Each stool sample was diluted to a 10% stool suspension in phosphate-buffered saline and stored at -70°C until use. The positive/negative status of these samples was confirmed by PCR (Seeplex Diarrhea-V ACE; Seegene, Seoul, Korea) and ELISA (RIDASCREEN Rotavirus test; R-Biopharm, Darmstadt, Germany). Samples determined to be positive by both PCR and ELISA were regarded as "true positive" samples, and samples determined to be negative by both methods were considered "true negative" samples. Samples that had discordant results between the two assays were excluded.
AFIAS rotavirus assay
The AFIAS rotavirus assay detects the rotavirus VP6 capsid antigen in stool samples, using the AFIAS-6 analyzer system (Boditech Med Inc.) and disposable AFIAS cartridge (Boditech Med Inc.). This assay uses sandwich immunoassay with detector mAbs (Mouse Anti-Rotavirus monoclonal antibody labeled with europium chelate) in a sample pad and capture mAbs (Mouse Anti-Rotavirus monoclonal antibody) immobilized on the nitrocellulose membrane in AFIAS cartridge [7] . Fifty microliters of the diluted stool sample was added to the sample pad containing a dried fluorescence-labeled detector antibody of the cartridge, and the sample was then moved onto the nitrocellulose membrane in the cartridge by capillary action. If the target rotavirus antigens were present in the sample, they would react with the fluoresence-labeled detector antibody to form an antigenantibody complex and would be moved and then captured by capture antibodies on the nitrocellulose membrane. After a reaction time of 12 minutes, the AFIAS-6 scanner (Boditech Med Inc.) measured the fluorescence intensity, which was expressed as a relative COI (cut-off index) value and was approximately proportional to the concentration of the rotavirus antigens in the sample. The sample result was interpreted as "positive" when the COI of the AFIAS−6 rotavirus assay was ≥ 1.0 and "negative" when COI was < 1.0. All procedures were performed according to the manufacturer's instructions.
Comparative assays
Multiplex PCR for rotavirus RNA detection
The Seeplex Diarrhea-V ACE detection kit was used to simultaneously detect Group A rotaviruses, adenovirus types 40 and 41 (species F), noroviruses GI and GII, and astroviruses. Viral RNA was extracted from the stool suspensions using a QIAamp Viral RNA Mini kit (Qiagen, Hilden, Germany) and the QIAcube platform (Qiagen). The nucleic acids were amplified on a PTC-200 thermal cycler (Bio-Rad, Hercules, CA, USA), and the PCR products were visualized after electrophoresis on an agarose gel. All procedures were performed according to the manufacturer's instructions. Stratec Biomedical AG, Birkenfeld, Germany). This assay also uses monoclonal antibodies against rotavirus VP6 capsid antigens. One hundred microliters of the diluted stool suspension was added to the microwell plate, and the assay was performed according to the manufacturer's instructions. The qualitative results (positive or negative) were read based on the calculated cut-off (optical density [OD] of negative control+0.15).
ELISA for rotavirus antigen detection
Immunochromatographic assay (ICA) for rotavirus antigen detection
The SD Bioline Rotavirus test (Standard Diagnostics, Yongin, Korea) is an ICA that automatically detects rotavirus VP6 capsid antigen in stool samples [8] . Three drops of diluted stool samples were added to the sample wells of the test device, and the results (positive or negative) were read with naked eyes after 15 minutes, according to the manufacturer's instructions.
Rotavirus VP7 and VP4 genotyping
Rotavirus G (VP7) and P (VP4) genotyping was carried out by reverse transcription (RT)-PCR and sequencing, using VP7-and VP4-specific primer sets [2] . RT-PCR was carried out with a Qiagen OneStep RT-PCR Kit (Qiagen), and PCR products were sequenced on an Applied Biosystems 3,500 Dx Genetic analyzer (Applied Biosystems, Foster City, CA, USA). Genotyping was performed by GenBank nucleotide Basic Local Alignment 
Repeatability and reproducibility
Negative, weak-positive, and positive controls of Group A rotaviruses were used to evaluate the reproducibility of the AFIAS rotavirus assay. Repeatability was tested in 10 replicates within a run, between-day precision was tested over five days using five replicates, and between-lot precision was tested using three different lots and five replicates per lot. The mean value and CV% of repeated tests for each concentration were calculated for withinrun variation, between-day variation, and between-lot variation.
Lower limit of detection (LLOD)
Culture supernatants of two types of rotavirus (American Type Culture Collection (ATCC) VR-2018, G1P [8] type; clinical isolate, G4P [6] type) were two-fold serially diluted with saline (1:2 to 1:512 dilutions) and used to evaluate the LLOD of the AFIAS rotavirus assay. Each diluted sample was tested in 20 replicates. The concentration of rotavirus was determined using real-time PCR (AccuPower diarrhea V1 multiplex RT-PCR kit assay, Bioneer Co., Daejeon, Korea) with in vitro-transcribed RNA calibrators, and the number of rotavirus RNA copies per milliliter was recorded for each sample. The LLOD of the AFIAS rotavirus assay was compared with that of the ICA and ELISA, using the same samples.
Cross-reactivity for other viruses, bacteria, and fungi
The potential for cross-reactivity with other viruses, bacteria, and fungi was examined using culture supernatants of the viruses and cultured colonies of the bacteria and fungi. The strains used to evaluate the cross-reactivity are shown in Table 1 .
Interference testing
Interference tests were performed with the following substances: 
Statistical analysis
The degree of agreement between AFIAS and other tests was assessed. We calculated positive, negative, and total agreement rate and kappa coefficient (κ) with 95% confidence intervals (CI) (where 0.001-0. 
RESULTS
Comparison of the AFIAS and ICA with PCR and ELISA Table 2 shows a comparison of AFIAS rotavirus assay and ICA with PCR and ELISA. Sensitivity, specificity, and overall agreement rates of the AFIAS assay compared with PCR and ELISA were 99.0% (95% CI: 94.7-99.8%), and 99.0% (95% CI: 94.7-99.8%), and 99.0% (95% CI: 96.5-99.7%, κ = 0.98), respectively. Similarly, sensitivity, specificity, and overall agreement rates of the ICA compared with PCR and ELISA were > 98% (κ = 0.98). The overall agreement among the four methods was 98.06%. Discrepant results among assays are shown in Table 3 . 
Detectability of rotavirus genotypes
The overall detectability rates of the rotavirus genotypes by AFIAS are presented in Table 4 . The following genotypes were detected: G1P [8] , G2P [4] , G3P [8] , G4P [6] , G4P [8] , G8P [4] , G8P [8] , G9P [4] , G9P [8] , GxP [4] , and GxP [8] . One sample of G1P [8] was not detected by the AFIAS rotavirus assay; this sample had a low OD (0.507) in ELISA and was also not detected by ICA.
Repeatability and reproducibility
The repeatability and reproducibility of AFIAS are shown in Table 5. All measurements for rotavirus-negative samples showed negative results. The within-run CVs for rotavirus weak-positive and positive samples were both 3.6%. The between-day CVs for weak-positive and positive samples were 3.6 and 3.9%, and be- tween-lot CVs were 3.9 and 4.7%, respectively.
LLOD
To determine the LLOD, 2-fold serial dilutions of the rotavirus G1P [8] (8.81 × 10 6 copies/mL) and G4P [6] culture supernatants were used. For the G1P [8] genotype, all 20 replicates of the 1:128-diluted sample (6.88 × 10 4 copies/mL) were positive, while all 20 replicates of the 1:256-diluted samples tested negative by AFIAS (Table 6 ). Therefore, the LLOD of AFIAS was 6.88 × 10 4 copies/mL for the G1P [8] type. The concentration of the G4P [6] culture supernatant was not measured. Comparison of the LLOD among AFIAS, ICA, and ELISA showed that AFIAS was eight times more sensitive than the ICA, and its sensitivity was similar to that of ELISA for detecting the G1P [8] genotype. Moreover, the sensitivity of AFIAS was four times that of ICA and ELISA for detecting the G4P [6] genotype.
Cross-reactivity and interference
Negative signals were obtained for all 16 viruses, 28 bacteria, two fungi, and other chemicals assayed, demonstrating no crossreactivity or interference in AFIAS (Table 1) .
DISCUSSION
In our assessment of the performance of AFIAS, we found high agreement rates between AFIAS and both PCR and ELISA. As there can be discrepant results between PCR and ELISA [9] [10] [11] , only samples that tested positive or negative by both methods were selected for further analysis with AFIAS. The agreement rate (99.0%) between AFIAS and both PCR and ELISA was sim-
